Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Income from Continuing Operations
Ocular Therapeutix Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Income from Continuing Operations
-$115.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Ocular Therapeutix Inc's Income from Continuing Operations?
Income from Continuing Operations
-115.3m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Income from Continuing Operations amounts to -115.3m USD.
What is Ocular Therapeutix Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-21%
Over the last year, the Income from Continuing Operations growth was -30%. The average annual Income from Continuing Operations growth rates for Ocular Therapeutix Inc have been 4% over the past three years , -13% over the past five years , and -21% over the past ten years .